State Street’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-835,909
Closed -$38.8M 4689
2023
Q2
$38.8M Buy
835,909
+37,625
+5% +$1.3M ﹤0.01% 1819
2023
Q1
$22.9M Buy
798,284
+4,332
+0.5% +$128K ﹤0.01% 2134
2022
Q4
$24.8M Buy
793,952
+299,623
+61% +$9.77M ﹤0.01% 2089
2022
Q3
$10M Buy
494,329
+74,106
+18% +$1.35M ﹤0.01% 2710
2022
Q2
$6.52M Buy
420,223
+194,283
+86% +$3.34M ﹤0.01% 2960
2022
Q1
$4.32M Buy
225,940
+38,446
+21% +$686K ﹤0.01% 3256
2021
Q4
$4.75M Buy
+187,494
New +$5.49M ﹤0.01% 3267

State Street's DICE Position: Q3 2023 in Review

State Street sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 835,909 shares — an estimated $38.8M sold.

State Street first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $38.8M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • State Street reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • State Street sold 835,909 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $38.8M.
  • State Street first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • State Street's DICE Therapeutics, Inc. Common Stock position peaked at $38.8M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on State Street's 13F filing for Q3 2023, filed 14 Nov 2023.